© Globe Newswire
15.12.2025
SIA
LISTED
TSX
Sienna Announces December Dividend
News Preview
MARKHAM, Ontario, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “Common Share”) for the month of December 2025, representing $0.936 per Common Share on an annualized basis....
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
ZTS
LISTED
NYSE
Zoetis Announces Proposed $1.75 Billion Convertible Senior Notes Offering
News Preview
Zoetis Inc. (NYSE: ZTS) (the “Company” or “Zoetis”) today announced that, subject to market conditions, it intends to offer $1.75 billion aggregate principal amount of convertible senior notes due 2029 (the “Notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
NEO
LISTED
NASDAQ
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation
News Preview
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that Natera voluntarily dismissed its appeal (and NeoGenomics thus dismissed its cross-appeal) of the North Carolina District Court’s August 2025 ruling. The dismissal will leave in place the ruling in NeoGenomics’ fa...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
15.12.2025
CPRX
LISTED
NASDAQ
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, Presiden...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
15.12.2025
VNDA
LISTED
NASDAQ
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
News Preview
WASHINGTON, Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP). Imsidolimab inhibits IL-36 recepto...
Themefolio
Profiler
Peergroup
© PR Newswire
15.12.2025
RDHL
LISTED
NASDAQ
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
News Preview
Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge, with leukemic cells persisting over time, even with combination therapy1Studies show that sphingosine kinase 2 (SPHK2) is overexpressed in venetoclax-resistant ca...
Themefolio
Profiler
Peergroup
© PR Newswire
15.12.2025
GRIN
LISTED
CSE
Grown Rogue's New Jersey Affiliate Celebrates One Year of Sales
News Preview
ABCO Garden State Selling Through Phase 1 with Phase 2 Construction UnderwayMEDFORD, Ore., Dec. 15, 2025 /CNW/ - Grown Rogue International Inc. ("Grown Rogue" or the "Company") (CSE: GRIN) (OTC: GRUSF), a flower-forward cannabis company combining craft values with disciplined execution, is pleased to update the investment community on the progress...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
XRAY
LISTED
NASDAQ
Dentsply Sirona Declares Quarterly Cash Dividend
News Preview
CHARLOTTE, N.C., Dec. 15, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on January 9, 2026, to holders of record as of...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
FBLG
LISTED
NASDAQ
FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
News Preview
HOUSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
VOR
LISTED
NASDAQ
Vor Bio Announces $150 Million Private Placement
News Preview
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share to a select group of institutional and accr...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
MBX
LISTED
NASDAQ
MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
News Preview
CARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will presen...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
BCAX
LISTED
NASDAQ
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
News Preview
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
15.12.2025
IMNM
LISTED
NASDAQ
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), in patients with progressing desmoi...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
PODD
LISTED
NASDAQ
Insulet Expands Omnipod® U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future
News Preview
Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod brand of products, has announced the expansion of its U.S. Pod recycling program, which is now available to all U.S. customers.
“Here at Insulet, our mission is to transform the lives of people with diabetes, and...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
CGC
LISTED
NASDAQ
Canopy Growth to Acquire MTL Cannabis; Transaction Expected to Create Canada’s Leading Medical Cannabis Business and Enhance Capacity to Serve Growing International Demand
News Preview
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) and MTL Cannabis Corp. (“MTL Cannabis” or “MTL”) (CSE: MTLC) (OTCQX: MTLNF) are pleased to announce that they have entered into a definitive arrangement agreement (the “Arrangement Agreement”) pursuant to which Canopy Growth will acquire all of the issued and ou...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
COR
LISTED
NYSE
Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology
News Preview
Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does not currently own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology, from TPG, a leading global alternative asset managem...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
ABEO
LISTED
NASDAQ
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
News Preview
CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company’s corporate strategy and business development functions, as well as drive operating efficienc...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
ORNBV
LISTED
HEL
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS15 December 2025 at 14.30 EET ...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
News Preview
THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
RVV
LISTED
CSE
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
News Preview
TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluatin...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
ZBIO
LISTED
NASDAQ
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
News Preview
- Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE -...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
JBIO
LISTED
NASDAQ
Jade Biosciences Announces $45 Million Private Placement
News Preview
SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a securities purchase agreement with BB Biotech fo...
Themefolio
Profiler
Peergroup
© Newsfile
15.12.2025
HBFG
LISTED
CSE
Happy Belly Food Group's Via Cibo Italian Fast-Casual Restaurant Signs a 10 Unit Development Agreement in Alberta
News Preview
Toronto, Ontario--(Newsfile Corp. - December 15, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands, is pleased to announce that it has signed an area development agreement for the province of Alberta for the contractual opening of ten (10) franchis...
Themefolio
Profiler
Peergroup
© Newsfile
15.12.2025
OSTX
LISTED
XASE
OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
News Preview
FDA confirmed that data from single-arm studies in rare diseases, such as in ultra-rare deadly pediatric cancer osteosarcoma, could support a Biologics Licensing Application (BLA) under Accelerated Approval Program pathway, as stated in FDA guidance documentsFDA proposed confirmatory study design include additional osteosarcoma disease settings suc...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
News Preview
Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 ...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
PVLA
LISTED
NASDAQ
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approve
News Preview
73% of trial participants (11/15 participants) improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment (Overall cVM-IGA) at Week 12; 67% of trial participants (10/15 participants) rated as “Much Improved” (+2) or “Very Much Improved” (+3) on the Overall cVM-IGA at Week 12...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.12.2025
MDCE
LISTED
OTC
Medical Care Technologies, Inc. (OTC Pink:MDCE) Completes First AI Consumer App Targeting Deployment Across 100+ Countries and 30 Languages
News Preview
Company to Launch AI Food & Recipe App to Access Trillion-Dollar Global Food Market While Advancing Medical AI Pipeline MESA, ARIZONA / ACCESS Newswire / December 15, 2025 / Medical Care Technologies, Inc. (OTC Pink:MDCE) today announced the completion of its first AI-based consumer application, marking a major milestone in the Company's strate...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.12.2025
IGC
LISTED
XASE
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines
News Preview
POTOMAC, MARYLAND / ACCESS Newswire / December 15, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today commented on recent federal policy momentum surrounding the potent...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.12.2025
JAGX
LISTED
NASDAQ
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
News Preview
SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) - for which the company completed a meeting in October 2025 with the FDA in support of a possible expedited approval pathway SAN FRANCISCO, CA / ACCESS Newswire / December 15, 2025 / Jaguar Health, Inc....
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.12.2025
AYTU
LISTED
NASDAQ
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
News Preview
EXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availabilityEXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, has no warnings or adverse events related to sexual dysfunction and no clinically significant weight gain co...
Themefolio
Profiler
Peergroup
© BusinessWire
15.12.2025
PLTR
LISTED
NASDAQ
Palantir Announces Renewal of Multi-Year Contract with the DGSI
News Preview
Palantir Technologies Inc. (NASDAQ: PLTR) announces a three-year renewal of its contract with the DGSI, France's domestic intelligence agency, extending a partnership that has been ongoing for nearly a decade. This agreement relates to the supply of Palantir’s proprietary software platform, as well as the integration, support, and assistance servi...
Themefolio
Profiler
Peergroup
© PR Newswire
15.12.2025
DXB
LISTED
ASX
DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT
News Preview
Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patientThe ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dosed in combination with standard-of-care blood pressure medication over 2 yearsOf the 286 adult patients dosed in...
Themefolio
Profiler
Peergroup
© PR Newswire
15.12.2025
DXB
LISTED
ASX
DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT
News Preview
Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patientThe ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dosed in combination with standard-of-care blood pressure medication over 2 yearsOf the 286 adult patients dosed in...
Themefolio
Profiler
Peergroup
© PR Newswire
15.12.2025
1873
LISTED
HKSE
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
News Preview
STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up to US$1.5 billion in total transaction value, includ...
Themefolio
Profiler
Peergroup
© PR Newswire
15.12.2025
1873
LISTED
HKSE
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
News Preview
STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up to US$1.5 billion in total transaction value, includ...
Themefolio
Profiler
Peergroup
© EQS Newswire
15.12.2025
HBMN
LISTED
SIX
HBM Healthcare Investments gibt Vereinbarung zum Verkauf einer Mehrheitsbeteiligung an Swixx Biopharma bekannt
News Preview
Die auf den Gesundheitssektor spezialisierte Beteiligungsgesellschaft HBM Healthcare Investments hat die Unterzeichnung einer verbindlichen Vereinbarung zum Verkauf einer Mehrheitsbeteiligung an Swixx Biopharma bekannt gegeben. Im Rahmen der Transaktion wird HBM Healthcare Investments, zusammen mit den Gründern und anderen Aktionären wie Mérieux Eq......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.12.2025
HBMN
LISTED
SIX
HBM Healthcare Investments Announces Agreement to Sell Majority of Investment in Swixx Biopharma
News Preview
HBM Healthcare Investments, an investment company focused on the healthcare sector, has announced the signing of a binding agreement to sell a majority stake in Swixx Biopharma. As part of the transaction, HBM Healthcare Investments, together with the founders and other shareholders such as Mérieux Equity Partners, will sell a majority of their cur......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.12.2025
RLF
LISTED
SIX
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
News Preview
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
GENEVA (Dec. 15, 2025) – MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company) announced today the completion of its business combination with NeuroX Group SA (NeuroX), a commercial-stage company delivering evidence-based, prec......
Themefolio
Profiler
Peergroup
© PR Newswire
15.12.2025
PPLPHARMA
LISTED
BSE
Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
News Preview
Piramal Pharma Solutions recently achieved a net promoter score (NPS) of 55, far surpassing industry averages. A third-party provider, DNV, validated the NPS survey and score. This accomplishment reflects the Organization's dedication to stakeholder centricity and operational excellence. MUMBAI, India, Dec. 15, 2025 /PRNewswire/ -- Piramal Pharma...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.12.2025
MRNA
LISTED
NASDAQ
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)
News Preview
mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the European Union, subject to authorization by the European Commission CAMBRIDGE, MA / ACCESS Newswire / December 15, 2025 / Moderna, Inc. (NASDAQ:MRNA)...
Themefolio
Profiler
Peergroup
© PR Newswire
15.12.2025
PPLPHARMA
LISTED
BSE
Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
News Preview
Piramal Pharma Solutions recently achieved a net promoter score (NPS) of 55, far surpassing industry averages. A third-party provider, DNV, validated the NPS survey and score. This accomplishment reflects the Organization's dedication to stakeholder centricity and operational excellence. MUMBAI, India, Dec. 15, 2025 /PRNewswire/ -- Piramal Pharma...
Themefolio
Profiler
Peergroup
© PR Newswire
15.12.2025
PPLPHARMA
LISTED
BSE
Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
News Preview
Piramal Pharma Solutions recently achieved a net promoter score (NPS) of 55, far surpassing industry averages. A third-party provider, DNV, validated the NPS survey and score. This accomplishment reflects the Organization's dedication to stakeholder centricity and operational excellence. MUMBAI, India, Dec. 15, 2025 /CNW/ -- Piramal Pharma Solutio...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
SAN
LISTED
EURONEXT
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
News Preview
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.12.2025
AMPH
LISTED
NASDAQ
Amphastar Announces FDA Approval for Teriparatide Injection
News Preview
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for teriparatide injection, USP 560 mcg/2.24mL (250 mcg/mL) single-patient-use prefilled pen....
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
SAN
LISTED
EURONEXT
Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
News Preview
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.12.2025
IBAB
LISTED
EURONEXT
Proton Therapy New Standard of Care for Patients with Oropharyngeal Cancer
News Preview
Louvain-La-Neuve, Belgium, December 15, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, is pleased to share today that, on December 11, The Lancet – one of the world’s most renowned academic journals – p...
Themefolio
Profiler
Peergroup
© PR Newswire
15.12.2025
1952
LISTED
HKSE
Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder
News Preview
SHANGHAI, Dec. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the launch of its 2030 Strategy, outlining a comprehensive five-year roadmap to drive sus...
Themefolio
Profiler
Peergroup
© PR Newswire
15.12.2025
ABBV
LISTED
EURONEXT
AbbVie Ranked #15 in the Inaugural Fortune 100 Best Companies to Work For Southeast Asia 2025 List
News Preview
SINGAPORE, Dec. 15, 2025 /PRNewswire/ -- AbbVie ASEAN has been ranked #15 in the inaugural Fortune Best Companies to Work For Southeast Asia 2025 list, in partnership with Great Place To Work®, highlighting workplaces across Singapore, Malaysia, Thailand and the Philippines....
Themefolio
Profiler
Peergroup
© PR Newswire
15.12.2025
CYP
LISTED
ASX
Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
News Preview
Announcement Highlights:Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease. The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CYP-001, or steroids plus placebo.Primary evaluation period exp...
Themefolio
Profiler
Peergroup
© PR Newswire
15.12.2025
CYP
LISTED
ASX
Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
News Preview
Announcement Highlights:Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease. The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CYP-001, or steroids plus placebo.Primary evaluation period exp...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.12.2025
RLF
LISTED
SIX
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
News Preview
GENEVA, SWITZERLAND / ACCESS Newswire / December 15, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics or the Company) announced today the completion of its business combination with NeuroX Group SA (NeuroX), a commercial-stage company delivering evidence-based, precision digital treatments for neurological diseases. The new...
Themefolio
Profiler
Peergroup
© BusinessWire
14.12.2025
IMNM
LISTED
NASDAQ
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company will host a conference call and webcast on Monday, December 15, 2025 at 8:30 am ET to disclose the topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an in...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.12.2025
KYTX
LISTED
NASDAQ
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
News Preview
– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET – – Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET –...
Themefolio
Profiler
Peergroup
© PR Newswire
14.12.2025
BRETEC
LISTED
HEL
Inside information: Bioretec has been granted FDA Breakthrough Device Designation status for its RemeOs™ DrillPin
News Preview
Bioretec Ltd Inside information 14 December 2025 at 5:45 p.m. EETTAMPERE, Finland, Dec. 14, 2025 /PRNewswire/ -- Bioretec Oy ("Bioretec" or the "Company"), a pioneer in biodegradable orthopedic implants, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its magnesium alloy technology-based, biodeg...
Themefolio
Profiler
Peergroup
© PR Newswire
14.12.2025
BRETEC
LISTED
HEL
Inside information: Bioretec has been granted FDA Breakthrough Device Designation status for its RemeOs™ DrillPin
News Preview
Bioretec Ltd Inside information 14 December 2025 at 5:45 p.m. EETTAMPERE, Finland, Dec. 14, 2025 /PRNewswire/ -- Bioretec Oy ("Bioretec" or the "Company"), a pioneer in biodegradable orthopedic implants, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its magnesium alloy technology-based, biodeg...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.12.2025
9969
LISTED
HKSE
InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial
News Preview
Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment....
Themefolio
Profiler
Peergroup
© PR Newswire
13.12.2025
SOBI
LISTED
STO
Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
News Preview
Expands Sobi's pipeline with a highly differentiated new Phase 3 asset in GoutAcquisition expected to be highly accretive to Sobi's mid- to long-term growth and margin trajectorySTOCKHOLM, Dec. 13, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) has entered into a definitive agreement to acquire Arthrosi Therapeutics, Inc. (Arthrosi), a private late-stage...
Themefolio
Profiler
Peergroup
© PR Newswire
13.12.2025
SOBI
LISTED
STO
Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
News Preview
Expands Sobi's pipeline with a highly differentiated new Phase 3 asset in GoutAcquisition expected to be highly accretive to Sobi's mid- to long-term growth and margin trajectorySTOCKHOLM, Dec. 13, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) has entered into a definitive agreement to acquire Arthrosi Therapeutics, Inc. (Arthrosi), a private late-stage...
Themefolio
Profiler
Peergroup
© BusinessWire
13.12.2025
SRRK
LISTED
NASDAQ
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Scholar Rock (NASDAQ: SRRK; the “Company”), today announced that the company granted inducement equity awards covering an aggregate of 7,800 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 4,457 shares of common stock and inducement restricted stock units, covering an aggr...
Themefolio
Profiler
Peergroup
© BusinessWire
13.12.2025
MLTX
LISTED
NASDAQ
Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired MoonLake Immunotherapeutics ("MoonLake" or the Company") (NASDAQ: MLTX) securities between March 10, 2024 and September 29, 2025, inc...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
